NSRX · Nasus Pharma Ltd. Ordinary Shares
View on chartInsiders & Stakes
| Dan Benjamin Teleman Chief Executive Officer | ▲ Buy | Open Market | 163,541 Shares held | 6/17/2026 | View profile |
Transaction History
| Dan Benjamin Teleman | ▲ Buy | Open Market | 6,550 | $20K | 6/17/2026 |
| Dan Benjamin Teleman | ▲ Buy | Open Market | 2,900 | $11K | 4/22/2026 |
| Dan Benjamin Teleman | ▲ Buy | Open Market | 15,000 | $31K | 3/31/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Nasus Pharma Enrolls First Patient in Phase 1 NS003 Study
Nasus Pharma has announced the enrollment and dosing of the first patient in a Phase 1 clinical study for NS003, an intranasal formulation of ondansetron. This marks a key early-stage milestone for the company's development pipeline. The stock is currently trading near its 52-week high, reflecting ongoing interest in these clinical updates.
Nasus Pharma Enrolls First Patient in Phase 1 NS003 Study. Nasus Pharma has announced the enrollment and dosing of the first patient in a Phase 1 clinical study for NS003, an intranasal formulation of ondansetron. This marks a key early-stage milestone for the company's development pipeline. The stock is currently trading near its 52-week high, reflecting ongoing interest in these clinical updates.